Minimally Invasive Surgery
Minimally Invasive Surgery Pedro T. Ramirez, Michael Frumovitz, and Pedro F. Escobar INTRODUCTION Minimally invasive surgery is currently considered a safe and viable option in the management…
Minimally Invasive Surgery Pedro T. Ramirez, Michael Frumovitz, and Pedro F. Escobar INTRODUCTION Minimally invasive surgery is currently considered a safe and viable option in the management…
Epithelial Ovarian Cancers:Low Malignant Potential andNon-Serous Ovarian Histologies Gregory P. Sfakianos, Angeles Alvarez Secord, and Ie-Ming Shih Epithelial ovarian cancer is the leading cause of death from gynecologic…
Targeted Therapy and Immunotherapy Robert L. Coleman and Paul J. Sabbatini COMPONENTS OF THE IMMUNE SYSTEM While simplistic in its view, the effectors of the immune system…
Breast Cancer and Related Diseases Catherine M. Dang and M. William Audeh Breast cancer is the most common malignancy in women throughout the world, and particularly in Westernized,…
Ancillary Procedures Joan L. Walker INTRAPERITONEAL CATHETER AND PORT PLACEMENT Procedure Overview The placement of an intraperitoneal (IP) catheter and access port should ideally occur at the…
Diagnostic Modalities David Starks, Bin Yang, and Peter G. Rose In the field of gynecologic oncology, the various diagnostic modalities available serve as invaluable tools in the diagnosis,…
Cervical Cancer Angela J. Ziebarth, Kenneth H. Kim, and Warner K. Huh Cervical cancer is one of the most common cancers in women worldwide. Nearly all invasive squamous…
Germ Cell and Sex Cord-Stromal Ovarian Cancers Susan C. Modesitt and Jubilee Brown Germ Cell Tumors Germ cell tumors of the ovary comprise fewer than 5% of…
Staging Procedures Summer B. Dewdney and Matthew A. Powell PROCEDURE OVERVIEW Box 29-1 Master Surgeon’s Corner Complete surgical staging including lymph node dissection, omentectomy, appendectomy, and…
Vaginal Cancer William J. Lowery, Junzo Chino, and Laura J. Havrilesky Primary vaginal cancer is an uncommon gynecologic malignancy and constitutes only 1% to 2% of gynecologic malignancies….